The above evidence suggested that both PI3K and AKT inhibitors enhanced the antiproliferation effect of MTH1 blockade or knockdown, indicating that the PI3K-AKT pathway activation may be an important determinant for the anti-glioma efficacy of MTH1 inhibition. Here, AKT1 is linked to glioma.